In people with chronic urticaria, Bilastine use is associated with significant improvements in clinical symptoms and quality of life.

A study was carried out for assessing Bilastine's safety and efficacy in the treatment of chronic urticaria symptoms and to offer an evidence-based reference for clinical rational drug usage.

For collecting studies on the impact of Bilastine on people with chronic urticaria, PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were comprehensively explored.  Two researchers independently reviewed the literature, collected data, and assessed the inclusion study's risk of bias. The meta-analysis was carried out with software RevMan5.4.

Overall, 7 trials and 975 patients were included. The skin quality of life index (Dermatology Life Quality Index, DLQI score, MD = −4.98), skin symptom score (Total Symptom Score, TSS, MD = −1.62), and  number of hives in a week (Urticaria activity score, UAS-7, MD = −25.28) were all considerably improved by Bilastine when compared to the control group. The differences were witnessed to be statistically significant.

Bilastine effectively improves clinical symptoms and quality of life in patients suffering from chronic urticaria.